STAT Plus: Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

George Yancopoulos, Regeneron Pharma’s top scientist, is still a bit bitter about the commercial flop of its cholesterol-lowering PCSK9 inhibitor Praluent.

Click to view original post